Conferences Genome editing using CRISPR and gene therapy captured attention during this year’s fully virtual ASH annual meeting. Early stage data showcasing the potential of both genome editing using CRISPR and gene therapy in non-malignant hematological disorders captured attention during this year’s fully virtual ASH annual meeting. A highlight of
